about
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.NOD2/CARD15 mutations in Polish and Bosnian populations with and without Crohn's disease: prevalence and genotype-phenotype analysis.Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXRThymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.Immunohistochemical analysis of thymidylate synthase expression in gastric carcinoma: correlation with clinicopathological parameters and survival.E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.Treatment of large colorectal neoplasms by endoscopic submucosal dissection: a European single-center study.Prevalence of Cryptosporidium sp. in patients with colorectal cancer.Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.Colorectal cancer and Cryptosporidium spp. infection.Diagnostic difficulties in a patient with Whipple’s diseaseIt is worth to examined larynx and hypopharynx during upper endoscopy?Polymorphism of GSTM1 gene in patients with colorectal cancer and colonic polypsIncreased PCNA/cyclin index correlates with severity of duodenitis defined by histological criteriaCryptosporidiosis in patients with colorectal cancer
P50
Q34030871-6984FBDF-44CC-4AE4-86BC-F2C650832466Q34705611-2636A4E5-F7E0-4F18-B310-8B4C29A180A3Q35749845-1E15991A-9BE9-47A1-9D19-DC705406B909Q36173223-D5480B39-8B6F-43A3-A122-EFA14815DF05Q37277642-BEEC7263-E529-49E7-B088-29F63F97B03EQ40728452-337D1EBB-A0D7-4067-A7EA-52014E23AAE5Q42748851-7C4EA6C2-651D-4A24-B940-35C7F57DAE69Q43106360-4663E30D-B065-407B-8D07-7BE1DE967326Q47794376-F7760E40-8C47-466A-9A72-FF296EB2F96CQ50669646-36D01251-3C03-411F-BF6A-713773622446Q50915584-31AE4D16-8829-488B-B2E8-04534F57A935Q54394304-1E76225B-557D-4B5A-913C-E353D062FD9FQ54947957-52D4B59F-FCA6-4257-9BA7-DE3CE8ED1611Q61945689-7E9A5317-CBB3-4D53-9F2E-BFA2812D9A0FQ61945690-5DAB909D-AE3B-47F8-9453-1CAA69D64E92Q61946738-7B95B6CE-22A9-481F-876A-D0BD7CECC32BQ72224162-BD4B201F-4E37-4C7F-8B40-269C44E5F077Q80601137-ECFDFFB6-7D21-4C8C-ACD1-9F2F7ED0C5A9
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9919-2695
@en
name
Dariusz Bielicki
@ast
Dariusz Bielicki
@en
Dariusz Bielicki
@es
Dariusz Bielicki
@nl
type
label
Dariusz Bielicki
@ast
Dariusz Bielicki
@en
Dariusz Bielicki
@es
Dariusz Bielicki
@nl
prefLabel
Dariusz Bielicki
@ast
Dariusz Bielicki
@en
Dariusz Bielicki
@es
Dariusz Bielicki
@nl
P214
P106
P1153
6701838940
P214
P31
P496
0000-0001-9919-2695
P735
P7859
viaf-313519468